Vestibular Schwannoma
62
12
17
19
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.5%
4 terminated out of 62 trials
82.6%
-3.9% vs benchmark
6%
4 trials in Phase 3/4
37%
7 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 19 completed trials
Clinical Trials (62)
Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
Selumetinib for NF2-Related Schwannomatosis
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Measuring Vestibular Organ Function With Weak Alternating Current Stimulation
Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
CI Following VS Removal or Labyrinthectomy
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas
Vestibular Schwannoma Organoids
Vestibular Rehabilitation Protocol in Unilateral Vestibular Schwannoma
Role of ChatGPT in Vestibular Schwannoma Management
Study of Aspirin in Patients With Vestibular Schwannoma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
StableEyes With Active Neurofeedback
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas
Mapping of Vestibular Centers Activation Using fMRI in Patients With Vestibular Schwannoma